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Introduction
Global clinical laboratory work performed under harmonized
operations is a central component for the successful conduct of
phase I–III clinical trials in multiple fields of science and medicine.
However, global harmonization of clinical laboratories for the
analysis of specimens from clinical trials operations (i.e., for safety,
diagnostic, endpoint laboratory assays) faces international chal-
lenges (e.g., laboratory logistical and technical factors), and it is
subject to different interpretations of regulations and guidance
materials published by the federal government, accrediting, and
non-accrediting organizations (e.g., Good Laboratory Practice
[GLP] [1], Clinical Laboratory Improvement Amendments
[CLIA] [2], College of American Pathologists [3], International
Organization for Standardization [ISO] 15189 [4], and Interna-
tional Conference on Harmonization [ICH] Good Clinical
Practice [GCP] [5]).
In an effort to harmonize and gain consensus on international
clinical laboratory operations, Good Clinical Laboratory Practice
(GCLP) guidelines were originated by merging GLP and ICH-GCP
principles, and were first published and copyrighted by the British
Association of Research Quality Assurance (BARQA) (BARQA-
GCLP) [6]. Subsequently, the Division of AIDS (DAIDS), National
Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health expanded the existing knowledge on GCLP
standards by publishing guidelines on GCLP (NIAID-GCLP) [7],
with increased implementation guidance based on applicable
portions of GLP, CLIA, the College of American Pathologists,
and the International Organization for Standardization (ISO
15189). Both of these GCLP approaches were created to ensure
that clinical laboratory results are reliable, repeatable, auditable,
and comparable between multiple clinical laboratories. Neverthe-
less, differences in the implementation of GCLP by clinical
laboratories have created critical inconsistencies for routine
management of operations in support of clinical trials and have
caused an urgent need to clarify and harmonize four central GCLP
elements for optimal management and clinical laboratory opera-
tions. These GCLP elements—discussed in this paper—are
training, auditing, assay validation, and proficiency testing.
The differences regarding the implementation of universal
standards of GCLP for clinical laboratory operations (i.e., clinical
laboratories performing safety, diagnostic, and endpoint assays) in
the conduct of clinical trials have been experienced in the HIV
study field. However, it is expected that this problem will have
broader implications in clinical trials, involving multiple fields.
This paper addresses for the first time an attempt to harmonize
these GCLP approaches into a single set of recommendations for
optimal operations and management that can be followed by
clinical laboratories, not only in the HIV field, but also possibly in
other science and medical fields.
Background
The Global HIV Vaccine Enterprise (GHAVE) [8] created an
alliance of independent organizations around the world dedicated
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discovery, product development, manufacturing, and clinical
trials. Both the International AIDS Vaccine Initiative (IAVI) and
DAIDS are globally recognized organizations and work collabo-
ratively in clinical trials under GHAVE. In the HIV field, clinical
laboratory standardization based on GCLP compliance is one of
GHAVE’s primary goals. Currently, within GHAVE there are two
approaches on how to achieve GCLP compliance in a clinical
laboratory environment. The first approach is followed by IAVI,
and it is based on BARQA-GCLP [6,9,10]. The second approach
is followed by DAIDS, and it is based on NIAID-GCLP [7]. The
two approaches cover the same general core elements [6,7], as
listed in Table 1: BARQA-GCLP and NIAID-GCLP Core
Elements.
The BARQA-GCLP guidelines were written in response to the
global adoption of the GCP guidelines to provide a framework to
organizations that undertake laboratory analysis of specimens
from clinical trials, on the facilities, systems, and procedures that
should be present to ensure the reliability, quality, and integrity of
the work, and to ensure that results are generated and reported to
satisfy GCP expectations. The BARQA-GCLP guidelines were
written purposely in a generic format to allow for sponsor
interpretation and implementation, but to meet the global
challenge of GCP compliance.
NIAID, as a sponsor of multiple HIV clinical trials, developed
the NIAID-GCLP guidelines with the objective of providing a
single unified document that encompasses sponsor requirements
and that embraces regulatory and guidance materials to guide the
conduct of clinical laboratory testing for human clinical trials. The
NIAID-GCLP is recognized as the minimum clinical laboratory
operation requirements to participate in DAIDS-sponsored
clinical trials.
Although both the BARQA-GCLP and the NIAID-GCLP
guidelines embrace clinical laboratories conducting safety, diag-
nostic, and endpoint assays in their distinctive approaches, they
differ in four critical GCLP elements for optimal management of
clinical laboratory operations: training, auditing, assay validation,
and proficiency testing. The latter four GCLP elements were
selected as they represent paramount stages in the conduct of
GCLP-compliant clinical studies supported by clinical laborato-
ries: from the general set-up (training of personnel and assay
validation) through the more specific elements of assay conduction
and laboratory oversight (audits, proficiency testing, and accred-
itation). Briefly, key issues pertaining to the four discrepant GCLP
elements according to the BARQA-GCLP and the NIAID-GCLP
guidelines are the following: (1) Training: since training for GCLP
is provided by different organizations following BARQA-GCLP
and NIAID-GCLP, it is crucial to define what constitutes training
within the GCLP boundaries. (2) Auditing: the BARQA-GCLP
guidelines support a systems approach to auditing, do not require
an audit checklist, and endorse laboratory accreditation for GCLP
compliance. In contrast, the NIAID-GCLP guidelines follow a
compliance approach to auditing, require an audit checklist, and
do not endorse laboratory accreditation for GCLP compliance. (3)
Assay validation: validating an assay consists of evaluating the
applicability of the parameters described in the ICH Q2A [11]
and Q2 (R1) [12] guidelines for relevance to an assay and its
intended use. The BARQA-GCLP guidelines are very generic on
the topic of assay validation, while the NIAID-GCLP guidelines
provide very detailed requirements in this matter. (4) Proficiency
testing: NIAID-GCLP guidelines describe a proficiency testing
program as a required external quality assurance program. The
BARQA-GCLP guidelines only mention that a laboratory should
subscribe to external proficiency schemes to demonstrate the
competency of the work performed.
Currently, clinical trial sponsors in the HIV study field are
requiring clinical laboratories to adhere to GCLP guidelines to
optimize laboratory operations and to strive for consistency and
integrity of results across multiple sites. In the HIV field,
pluripotent clinical laboratories are faced with the following
question: which of the two main GCLP (BARQA-GCLP or
NIAID-GCLP) approaches should be followed to become GCLP
compliant, meet GCLP expectations from different sponsors, and
obtain consistent laboratory results across trials and sites? These
clinical laboratories must have minimum and common levels of
standardization within the interpretation and implementation of
GCLP, so that consistent and reliable results are obtained in
support of clinical trials and can be submitted to regulatory health
authorities. As experienced in the HIV field, clinical laboratories
supporting clinical trials in other fields of science and medicine are
facing a similar situation [13].
Purpose and Scope
The purpose of this paper is to propose a harmonized
interpretation of the four GCLP critical elements listed above,
for optimal management of clinical laboratory operations, which
are critical for successful conduction of clinical trials. These GCLP
elements were selected upon reviewing inconsistencies in the
BARQA-GCLP and the NIAID-GCLP guidelines, which have
affected the harmonization of clinical laboratory operations. The
ultimate goal of this paper is to raise public awareness on the need
to harmonize GCLP for clinical laboratory operations to optimally
support clinical trials, and to call on the attention of the United
States Food and Drug Administration, the Organization for
Economic Co-operation and Development, the European Med-
icines Agency, and all other regulatory agencies worldwide to
consider the information presented here, so that universal GCLP
standards are developed. This paper was originated from a group
of authors with expertise in phase I–III HIV clinical trials, GCLP,
and regulatory materials such as GLP [14] and GCP, who
convened the ‘‘Workshop on GCLP Guidelines for International
Clinical Trials: Interpretation and Implementation’’ (October 9–
10, 2007, in Raleigh, North Carolina [15]), but its scope extends to
other study fields, such as cancer, malaria, tuberculosis, stem cell,
or other therapeutic interventions.
Table 1. BARQA-GCLP and NIAID-GCLP core elements.
BARQA-GCLP NIAID-GCLP
Organization and personnel Organization and personnel
Facilities Physical facilities
Equipment, materials, and reagents Equipment, test, and control
Standard operating procedures Testing facility operations
Planning, conduct, and reporting Specimen transport and management;
laboratory information system;
verification of performance; records
and reports; personnel safety
Quality audit Quality management
Quality control See: Test and control
Storage and retention of records See: Records and reports
Confidentiality See: Records and reports
doi:10.1371/journal.pmed.1000067.t001
PLoS Medicine | www.plosmedicine.org 2 May 2009 | Volume 6 | Issue 5 | e1000067GCLP Recommendations
This section consists of the GCLP recommendations agreed
upon by the authors during the Workshop and from follow-up
sessions.
Training
The sponsor of a clinical trial or study is responsible for ensuring
that all individuals working on or supporting a clinical trial have
the appropriate experience or training to perform their functions.
Laboratory management is responsible for developing minimum
requirements for training per their site’s experience and capability.
Training of laboratory and support staff should have two main
constituents: (1) training to perform the job and (2) training for in-
study protocol requirements. Each laboratory conducting safety,
diagnostic, and endpoint assays should have a documented and
ongoing training program and routine assessment of competence
in the performance of the individual’s role. Each site should
maintain individual training records for all staff members, which
confirm the training received and the level of competency
attained.
GCLP training is recommended for any member of the
laboratory staff involved in work that supports a clinical trial. At
a minimum, the clinical laboratory manager must be appropriately
trained and qualified to perform his/her role and have received
GCLP training. Similarly, staff working within the clinical
laboratory should be suitably trained and qualified in those parts
of GCLP applicable to the work they perform.
There are different GCLP trainings offered by different
organizations following BARQA-GCLP or NIAID-GCLP, and
the training effectiveness may vary based on the experience or skill
of the trainer. GCLP training should be provided by a recognized
institution/accrediting body or experienced trainer. A GCLP
trainer must have an in-depth understanding of GCLP gained by
working in the environment and must be experienced and
proficient at educating and competent in communicating to a
trainee the requirements of GCLP. It is recommended that
laboratory management verify the credentials of a trainer or an
organization before obtaining GCLP training.
Auditing
Periodic audits of clinical laboratories involved in the conduct of
a clinical trial should be performed. The frequency of audits is
determined based on sponsors’ requirements and specific clinical
laboratory needs to meet GCLP. GCLP sponsor audits of a clinical
laboratory should follow a sponsor-approved master audit plan
that covers the elements of GCLP to ensure compliance with the
appropriate regulations, protocols, standard operating procedures,
and analytical plans. A generic example is provided in Text S1:
Example of a GCLP Master Audit Plan.
It is recommended that an audit checklist be used as a tool to
assist auditors in consistently reviewing categories and specific
processes applicable to each clinical laboratory site within a
clinical trial and to document progress over time. An example of a
checklist is provided in Text S2: Example of an Audit Checklist.
An audit is a sponsor-driven laboratory (e.g., clinical laboratory)
assessment related to a trial or study; as opposed to GCLP
accreditation, which is an independent assessment of a laboratory
(e.g., clinical laboratory) to operate in accordance with GCLP
irrespective of the sponsor of a trial or study. Although one
accrediting body should give confidence to any sponsor that a
facility operates following GCLP standards, GCLP accreditation is
not yet globally provided by regulatory agencies and there is no
governing body overseeing the accreditation process. The latter
represents a gap in the GCLP field to be addressed by regulatory
agencies worldwide. Qualogy, an independent organization,
currently provides GCLP accreditation, endorsed by IAVI. A
Qualogy GCLP-accredited clinical laboratory is assessed for
compliance annually for the first three years, and every two years
thereafter. In contrast, NIAID does not endorse accreditation for
its sponsored laboratories, but provides guidance for GCLP
compliance on a continuous and as needed basis. Likewise,
NIAID-sponsored laboratories are assessed for GCLP compliance
with a frequency that is determined by the sponsor and based on
the specific laboratory needs. The frequency of GCLP laboratory
assessment can be as minimal as once per year. While consensus
was not reached on the GCLP accreditation requirement, the
authors did agree on the need for external auditing of laboratories
for GCLP compliance and that laboratories that have obtained
accreditation status should still perform internal quality assurance
audits. The lack of consensus on GCLP accreditation requirement
reflects the technical gap existing in the GCLP field that needs to
be addressed by regulatory health authorities worldwide; an
evolution of the GCLP field that is out of the scope of the present
paper. Additionally, the authors agree that the management of a
clinical laboratory must evaluate the risks and costs associated with
obtaining or not obtaining GCLP accreditation. The authors wish
to raise awareness on the issue of GCLP accreditation and the
need to establish a global accrediting body.
Assay Validation
All methods used for safety or endpoint analyses in clinical trials
need to be appropriately validated and demonstrably fit for
purpose. Methods defined as waived by CLIA, or methods
introduced prior to April 2003, do not require validation [2]. For
non-waived CLIA assays, such as immunogenicity endpoint
assays, appropriate ICH Q2A and Q2 (R1) guidelines [11,12]
for assay validation should be used by clinical trial laboratories to
demonstrate fitness for purpose of the assay in question [16–19].
Validating an assay consists of evaluating the applicability of the
parameters described in the ICH Q2 guidelines for relevance to
the assay and its intended use: accuracy, precision, limit of
detection, limit of quantitation, specificity, linearity and range,
ruggedness/robustness, and system suitability. However, it is at the
discretion of the validating clinical laboratory conducting endpoint
assays to define, based on statistical analysis, the critical
parameters that are necessary to validate an assay. For example,
if a ‘‘gold standard’’ assay does not exist for measuring the analyte
in question, accuracy, as defined by the guidance document,
cannot be addressed, as it is a specific comparison to a ‘‘gold
standard’’ assay. This does not preclude one from validating the
assay for other parameters such as precision, linearity, limits of
detection, and quantitation. The process of assay validation
involves qualification of the assay and the establishment of pass/
fail criteria to be used for final assay validation. By no means
should simple intra- and inter-laboratory comparison, and/or the
use of positive/negative controls for an assay, be considered assay
validation. Finally, in the absence of a generalized proficiency
testing program, a validated assay can be transferred to another
clinical laboratory through demonstration of concordance with the
clinical laboratory in which the assay was validated or another that
has successfully transferred the assay.
Proficiency Testing
A proficiency testing program consists of an evaluation of data,
provided by multiple clinical laboratories using assays capable of
identifying the same analyte or diagnostic outcome on the same set
of samples, by a central unit that statistically analyzes the data. The
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compared to the others or, when available, to a ‘‘gold standard.’’
Proficiency testing programs for many of the routine hematology
and biochemistry assays do exist, and clinical laboratories should
participate in these programs, where applicable.
A proficiency testing program for a new clinical endpoint assay
should be based on the detection and/or quantitation of specific
analytes under predetermined laboratory conditions and proce-
dures and should be provided on a routine basis [20–25]. The
proficiency program should consist of the following, when possible:
(1) A standardized set of specimens that contain the analytes to be
detected. These analytes should be tested by a large enough
sampling of laboratories to establish a statistically relevant mean
(‘‘gold standard’’) of the results measured under the proficiency
testing. (2) A defined kit or a set of reagents, materials, and
equipment that should be available to all participating laborato-
ries. (3) A set of general and assay-specific instructions for the
conduct of the proficiency testing. The general instructions should
also include the defined criteria of outcome acceptability based on
its statistical similarity/dissimilarity to the mean results of the
assays being assessed by all participating laboratories. A reporting
structure should exist to inform laboratories if their results are
within the acceptable range. Results that are outside of the
established range (outliers) should be investigated to determine if
improved protocols resulted in better detection of the analyte while
maintaining a low background and false positive rate. (4)
Frequency of proficiency testing will be determined based on the
inherent variability and complexity of the assay being tested,
laboratory needs, and sponsor requirements.
For many immunogenicity assays, there is no ‘‘gold standard’’
currently available, and participants’ results will establish the ‘‘gold
standard’’ value over time. The larger the number of participating
laboratories, and the greater the frequency of the proficiency
testing, the greater the confidence will be in generating the
relevant mean. Irrespective of the existence of a proficiency
scheme, GCLP-compliant laboratories should regularly evaluate
the performance of assays for accuracy and precision through
trend analysis of a consistent positive control. Each individual
laboratory should determine the frequency of internal laboratory
testing, based on their specific needs.
Pass/fail criteria for a proficiency testing program is based on
the statistical similarity of the results of an individual laboratory
when compared to the mean of the results of all participating
laboratories. Therefore, it is important that proficiency testing
reports include summary statistics and graphical presentations of
performance of each laboratory along with the mean of results
obtained by all participating laboratories. Performance testing is
not about passing or failing; it is about identifying a drift of an
assay and the need to take actions to investigate the causes of the
drift and to correct them for consistency of results over time and
across multiple laboratories. As an example, in the performance
testing of immunological assays, a coefficient of variation of less
than 30% for cell-based assays and ,10% for humoral (ELISA)-
based assays is considered acceptable [26].
Benefits
Standardized GCLP requirements would benefit clinical
laboratories conducting safety, diagnostic, and endpoint assays in
support of clinical trials and would potentially benefit other
laboratories globally, both by providing a consistent direction in
GCLP compliance, and by allowing laboratories to put into
practice a unified set of GCLP-defined procedures that will
enhance reproducibility and reliability of results. The latter is
especially critical when conducting trials that use multiple
international laboratory sites.
Conclusions
Harmonization exists among global organizations as to the need
for a quality system in clinical laboratories that analyze specimens
from clinical trials. The authors reached a consensus that GCLP
compliance is the minimal requirement that clinical laboratories
should meet to increase adherence to standardized practices and
procedures, optimize management operations of clinical labora-
tories, and enhance obtaining reproducible and reliable results,
while ensuring the safety of human research participants.
General consensus on three out of the four selected GCLP
elements was reached and presented as GCLP recommendations
of this paper. The authors recognize that individual study sponsors
may apply sponsor-specific standards for the implementation of
GCLP elements across different areas of their studies and that
sufficient flexibility exists in how compliance with such elements
should be met. One such example may be the frequency of GCLP
training for the clinical laboratory staff: it was agreed that staff
should receive GCLP training, but the frequency of such training
will be decided by the clinical laboratory management and the
study sponsor. The GCLP element regarding clinical laboratory
accreditation for GCLP compliance remains open, since at the
present time there is no international, universal, and publicly
available accrediting organization acceptable to all parties
involved in clinical trials worldwide. With time, and as the GCLP
standard becomes globally accepted, GCLP accreditation will find
a place in the implementation of GCLP for laboratories. It is the
authors’ wish to raise awareness on the issue of GCLP
accreditation and on the need to establish a global accrediting
body.
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